Meg Tirrell
Bloomberg
The Bill & Melinda Gates Foundation invested $10 million in Liquidia Technologies, a closely held biotechnology company developing vaccines, as part of a $400 million initiative to fund activities to help poorer countries.
Liquidia is developing a seasonal flu vaccine and has an agreement with the PATH Malaria Vaccine Initiative to use its technology to work on new malaria vaccines, the Research Triangle Park, North Carolina-based company said today in an e- mailed statement. The $400 million program provides low-interest loans, loan guarantees and equity investments to help finance organizations that meet the group’s focus areas.
Microsoft Corp. (MSFT) Chairman and co-founder Bill Gates, in his 2010 annual foundation letter, highlighted the need for a malaria vaccine to eradicate the disease, calling it “the highest-risk malaria work we fund.” The foundation has supplied $13.8 billion in global health funding since 1994, according to its website.
RELATED ARTICLE:
Bill Gates Funds GM Mosquitoes to Combat Dengue
Viruses and the GM Insect “Flying Vaccine” Solution
RELATED VIDEO:
Bill Gates says Anti-vaccine Advocates “Kill Children”
Be the first to comment on "Gates Foundation Invests $10 Million in Vaccines Developer"